{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:13:28Z","timestamp":1779380008750,"version":"3.53.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chitosan nanoparticles (CS NPs) showed promising results in drug, vaccine and gene delivery for the treatment of various diseases. The considerable attention towards CS was owning to its outstanding biological properties, however, the main challenge in the application of CS NPs was faced during their size-controlled synthesis. Herein, ionic gelation reaction between CS and sodium tripolyphosphate (TPP), a widely used and safe CS cross-linker for biomedical application, was exploited. The development of nanodelivery platform, namely Sorafenib-loaded chitosan nanoparticles (SF\u2013CS NPs), was constructed in order to improve SF drug delivery to human Hepatocellular Carcinoma (HepG2) cell lines. The NPs were artificially fabricated using an ionic gelation technique. A number of CS NPs that had been loaded with an SF were prepared using different concentrations of sodium tripolyphosphate (TPP). These concentrations were 2.5, 5, 10, and 20\u00a0mg\/mL, and they are abbreviated as SF\u2013CS NPs 2.5, SF\u2013CS NPs 5.0, SF\u2013CS NPs 10, and SF\u2013CS NPs 20 respectively. DLS, FTIR, XRD, HRTEM, TGA, and FESEM with EDX and TEM were used for the physiochemical characterisation of SF\u2013CS NPs. Both DLS and HRTEM techniques demonstrated that smaller particles were produced when the TPP content was raised. In a PBS solution with a pH of 4.5, the SF exhibited efficient release from the nanoparticles, demonstrating that the delivery mechanism is effective for tumour cells. The cytotoxicity investigation showed that their anticancer effect against HepG2 cell lines was significantly superior than that of free SF. In addition, the nanodrug demonstrated an absence of any detectable toxicity to normal adult human dermal fibroblast (HDFa) cell lines. This is a step towards developing a more effective anticancer medication delivery system with sustained-release characteristics, which will ultimately improve the way cancer is managed.<\/jats:p>","DOI":"10.1038\/s41598-023-38054-4","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T15:02:44Z","timestamp":1690470164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Fabrication and characterization of nanodelivery platform based on chitosan to improve the anticancer outcome of sorafenib in hepatocellular carcinoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Fahad","family":"Albalawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Zobir","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharida","family":"Fakurazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mas Jaffri","family":"Masarudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"3","key":"38054_CR1","doi-asserted-by":"publisher","first-page":"e0265668","DOI":"10.1371\/journal.pone.0265668","volume":"17","author":"SI Choi","year":"2022","unstructured":"Choi, S. I. et al. Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts. PLoS ONE 17(3), e0265668. https:\/\/doi.org\/10.1371\/journal.pone.0265668 (2022).","journal-title":"PLoS ONE"},{"issue":"19","key":"38054_CR2","doi-asserted-by":"publisher","first-page":"10774","DOI":"10.3390\/ijms221910774","volume":"22","author":"N Juaid","year":"2021","unstructured":"Juaid, N. et al. Anti-hepatocellular carcinoma biomolecules: Molecular targets insights. Int. J. Mol. Sci. 22(19), 10774. https:\/\/doi.org\/10.3390\/ijms221910774 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"38054_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang, W. et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: Theoretical basis and therapeutic aspects. Signal Transduct. Target. Ther. 5, 87. https:\/\/doi.org\/10.1038\/s41392-020-0187-x (2020).","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"38054_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0159-1","volume":"50","author":"C M\u00e9ndez-Blanco","year":"2018","unstructured":"M\u00e9ndez-Blanco, C. et al. Sorafenib resistance in hepatocarcinoma: Role of hypoxia-inducible factors. Exp. Mol. Med. 50(10), 1\u20139. https:\/\/doi.org\/10.1038\/s12276-018-0159-1 (2018).","journal-title":"Exp. Mol. Med."},{"key":"38054_CR5","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.18632\/oncotarget.26579","volume":"10","author":"KT Mahendra","year":"2019","unstructured":"Mahendra, K. T. et al. Myeloid cell leukemia-1 dependence in acute myeloid leukemia: A novel approach to patient therapy. Oncotarget 10, 1250\u20131265 (2019).","journal-title":"Oncotarget"},{"key":"38054_CR6","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.3892\/ol.2018.8010","volume":"15","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Sorafenib inhibited cell growth through the MEK\/ERK signaling pathway in acute promyelocytic leukemia cells. Oncol. Lett. 15, 5620\u20135626. https:\/\/doi.org\/10.3892\/ol.2018.8010 (2018).","journal-title":"Oncol. Lett."},{"key":"38054_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/oaju.s723","volume":"3","author":"F Zustovich","year":"2011","unstructured":"Zustovich, F. et al. Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. Open Access J. Urol. 3, 69\u201382. https:\/\/doi.org\/10.2147\/oaju.s723 (2011).","journal-title":"Open Access J. Urol."},{"issue":"1","key":"38054_CR8","doi-asserted-by":"publisher","first-page":"012028","DOI":"10.1088\/1757-899x\/757\/1\/012028","volume":"757","author":"MKA Mohammed","year":"2020","unstructured":"Mohammed, M. K. A., Mohammad, M., Jabir, M. S. & Ahmed, D. S. Functionalization, characterization, and antibacterial activity of single wall and multi wall carbon nanotubes. IOP Conf. Ser. 757(1), 012028. https:\/\/doi.org\/10.1088\/1757-899x\/757\/1\/012028 (2020).","journal-title":"IOP Conf. Ser."},{"issue":"3","key":"38054_CR9","doi-asserted-by":"publisher","first-page":"035003","DOI":"10.1088\/2053-1591\/aab0ed","volume":"5","author":"KS Khashan","year":"2018","unstructured":"Khashan, K. S., Jabir, M. S. & Abdulameer, F. A. Carbon Nanoparticles decorated with cupric oxide nanoparticles prepared by laser ablation in liquid as an antibacterial therapeutic agent. Mater. Res. Express 5(3), 035003. https:\/\/doi.org\/10.1088\/2053-1591\/aab0ed (2018).","journal-title":"Mater. Res. Express"},{"issue":"2","key":"38054_CR10","first-page":"105","volume":"4","author":"M Mudgil","year":"2012","unstructured":"Mudgil, M., Gupta, N., Nagpal, M. & Pawar, P. Nanotechnology: A new approach for ocular drug delivery system. Int. J. Pharm. Pharm. Sci. 4(2), 105\u2013112 (2012).","journal-title":"Int. J. Pharm. Pharm. Sci."},{"issue":"14","key":"38054_CR11","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1080\/10667857.2022.2133073","volume":"37","author":"MS Jabir","year":"2022","unstructured":"Jabir, M. S. et al. Gold nanoparticles loaded TNF-\u03b1 and CALNN peptide as a drug delivery system and promising therapeutic agent for breast cancer cells. Mater. Technol. 37(14), 3152\u20133166. https:\/\/doi.org\/10.1080\/10667857.2022.2133073 (2022).","journal-title":"Mater. Technol."},{"key":"38054_CR12","doi-asserted-by":"publisher","first-page":"012077","DOI":"10.1088\/1757-899x\/454\/1\/012077","volume":"454","author":"MS Jabir","year":"2018","unstructured":"Jabir, M. S., Nayef, U. M., Jawad, K. H., Taqi, Z. J. & Ahmed, N. A. Porous silicon nanoparticles prepared via an improved method: A developing strategy for a successful antimicrobial agent against Escherichia coli and Staphylococcus aureus. IOP Conf. Ser. 454, 012077. https:\/\/doi.org\/10.1088\/1757-899x\/454\/1\/012077 (2018).","journal-title":"IOP Conf. Ser."},{"key":"38054_CR13","doi-asserted-by":"publisher","first-page":"167569","DOI":"10.1016\/j.ijleo.2021.167569","volume":"244","author":"T Rashid","year":"2021","unstructured":"Rashid, T., Nayef, U. M., Jabir, M. S. & Mutlak, F. A. Synthesis and characterization of Au:ZnO (core:shell) nanoparticles via laser ablation. Optik 244, 167569. https:\/\/doi.org\/10.1016\/j.ijleo.2021.167569 (2021).","journal-title":"Optik"},{"key":"38054_CR14","first-page":"79","volume":"14","author":"Z Ali","year":"2019","unstructured":"Ali, Z., Jabir, M. & Al-Shammari, A. Gold nanoparticles inhibiting proliferation of Human breast cancer cell line. Res. J. Biotechnol. 14, 79\u201382 (2019).","journal-title":"Res. J. Biotechnol."},{"key":"38054_CR15","doi-asserted-by":"publisher","DOI":"10.5101\/nbe.v11i1.p35-43","author":"HA Kadhem","year":"2019","unstructured":"Kadhem, H. A. et al. Zinc oxide nanoparticles induces apoptosis in human breast cancer cells via caspase-8 and P53 pathway. Nano Biomed. Eng. https:\/\/doi.org\/10.5101\/nbe.v11i1.p35-43 (2019).","journal-title":"Nano Biomed. Eng."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38054-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38054-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38054-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T15:04:11Z","timestamp":1690470251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38054-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38054"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-38054-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"21 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12180"}}